- Home
- NUVL vs FRPT Comparison
NUVL vs FRPT Comparison
Compare NUVL & FRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- FRPT
- Stock Information
- Founded
- NUVL 2017
- FRPT 2004
- Country
- NUVL United States
- FRPT United States
- Employees
- NUVL N/A
- FRPT N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- FRPT Packaged Foods
- Sector
- NUVL Health Care
- FRPT Consumer Staples
- Exchange
- NUVL Nasdaq
- FRPT Nasdaq
- Market Cap
- NUVL 6.7B
- FRPT 6.5B
- IPO Year
- NUVL 2021
- FRPT 2014
- Fundamental
- Price
- NUVL $87.30
- FRPT $145.19
- Analyst Decision
- NUVL Strong Buy
- FRPT Strong Buy
- Analyst Count
- NUVL 10
- FRPT 15
- Target Price
- NUVL $112.60
- FRPT $160.13
- AVG Volume (30 Days)
- NUVL 350.8K
- FRPT 467.6K
- Earning Date
- NUVL 11-12-2024
- FRPT 11-04-2024
- Dividend Yield
- NUVL N/A
- FRPT N/A
- EPS Growth
- NUVL N/A
- FRPT N/A
- EPS
- NUVL N/A
- FRPT 0.88
- Revenue
- NUVL N/A
- FRPT $927,890,000.00
- Revenue This Year
- NUVL N/A
- FRPT $29.89
- Revenue Next Year
- NUVL N/A
- FRPT $24.58
- P/E Ratio
- NUVL N/A
- FRPT $165.47
- Revenue Growth
- NUVL N/A
- FRPT 29.36
- 52 Week Low
- NUVL $61.80
- FRPT $82.16
- 52 Week High
- NUVL $113.51
- FRPT $160.91
- Technical
- Relative Strength Index (RSI)
- NUVL 36.14
- FRPT 40.13
- Support Level
- NUVL $84.64
- FRPT $143.00
- Resistance Level
- NUVL $89.31
- FRPT $149.06
- Average True Range (ATR)
- NUVL 2.82
- FRPT 3.50
- MACD
- NUVL -0.72
- FRPT -1.32
- Stochastic Oscillator
- NUVL 20.93
- FRPT 13.54
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. The former two store types accounted for 89% of 2023 sales, with grocery stores representing the primary driver of footprint growth. Freshpet primarily targets dogs (92% of sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 96% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.